Status:
RECRUITING
Maintenance of an Antiaggregation by Acetylsalicylic Acid, While a Extracorporeal Lithotripsy Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Renal Lithiasis
Antiplatelet
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background/Rationale for the study: Lithiasis pathology is increasingly common because of the change in our lifestyle and our food. Thus, we hold a prevalence for urinary lithiasis 10% in France curr...
Detailed Description
Before the ECL: Patients will be recruited during the urology consultation prior to the lithotripsy for kidney stones Kidneys (JJ stent in place or not) using an uninjected abdominal-pelvic or ultras...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Over 18 yo patients
- Patients with 1 renal lithiasis (at least) requiring treatment with extracorporeal lithotripsy
- Patients taking Kardégic 75 (monotherapy
- Exclusion Criteria:
- Patients with known (or previously known) bleeding disorders on the pre-treatment assessment
- Patients with anticoagulant therapy or other anti-aggregating therapy (eg Kardegic at 75mg, AVK, NACO, LMWH, HNF, P2Y12 inhibitor)
- Patients with another contrindication to the ECL.
- Patients with prescription of more than the outset 1 ECL session
- Tutelage, curatorship, justice safeguarding, deprived of liberties, unaffiliated SS, impaired comprehension abilities, pregnant and lactating women.
Exclusion
Key Trial Info
Start Date :
January 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03437057
Start Date
January 8 2018
End Date
March 1 2027
Last Update
January 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003